SEC Filings

Form 10-Q
MYOKARDIA INC filed this Form 10-Q on 05/09/2019
Document Outline
Entire Document (4197.1 KB)
Subdocument 1 - 10-Q - 10-Q
Page 1 - UNITED STATES
Page 2 - MYOKARDIA, INC.
Page 3 - PART I FINANCIAL INFORMATION
Page 4 - MYOKARDIA, INC.
Page 5 - MYOKARDIA, INC.
Page 6 - MYOKARDIA, INC.
Page 7 - MYOKARDIA, INC.
Page 8 - Accounting Policies - Leases
Page 9 - Adopted Accounting Pronouncements - Other
Page 10 - History of the Collaboration Agreement
Page 11 - Contract Term
Page 12 - Cost Sharing
Page 13 - 4. Fair Value Measurements
Page 14 - N/A
Page 15 - 5. Leases
Page 16 - 6. Balance Sheet Components
Page 17 - 7. Commitments and Contingencies
Page 18 - 9. Stock-Based Compensation
Page 19 - 11. Income taxes
Page 20 - You should read the following management s discussion and analysis of our financial condition and re
Page 21 - N/A
Page 22 - Sanofi License and Collaboration Agreement
Page 23 - Operating Expense
Page 24 - General and Administrative Expenses
Page 25 - Cash Flows
Page 26 - Off-Balance Sheet Arrangements
Page 27 - PART II OTHER INFORMATION
Page 28 - We will need to raise additional funding, which may not be available on acceptable terms, or at all.
Page 29 - Our reported financial results may be adversely affected by changes in accounting principles general
Page 30 - We depend heavily on the success of mavacamten and MYK-491, our initial product candidates. Other th
Page 31 - We may encounter substantial delays in our clinical trials or we may fail to demonstrate safety and
Page 32 - We may find it difficult to enroll patients in our clinical trials, which could delay or prevent cli
Page 33 - We may not be successful in our efforts to identify or discover potential product candidates.
Page 34 - Risks Related to Government Regulation
Page 35 - Even if we complete the necessary preclinical studies and clinical trials, we cannot predict when or
Page 36 - We may seek one or more special designations from regulatory authorities for our product candidates,
Page 37 - Risks Related to Our Reliance on Third Parties
Page 38 - We expect to rely on third parties to conduct some or all aspects of our protocol development, resea
Page 39 - Risks Related to Our Intellectual Property
Page 40 - If we are unable to protect the confidentiality of our trade secrets, our business and competitive p
Page 41 - We may be involved in lawsuits to protect or enforce our patents or the patents of our licensors, wh
Page 42 - Risks Related to Commercialization and the Market for Our Product Candidates
Page 43 - The insurance coverage and reimbursement status of newly-approved products targeting small patient p
Page 44 - N/A
Page 45 - We face significant competition from other biotechnology and pharmaceutical companies, and our opera
Page 46 - Healthcare legislative changes may have a material adverse effect on our business and results of ope
Page 47 - Our future success depends on our ability to retain key employees and consultants, including our sci
Page 48 - Inadequate funding for the FDA, the SEC and other government agencies could hinder their ability to
Page 49 - If we fail to comply with environmental, health and safety laws and regulations, we could become sub
Page 50 - We or the third parties upon whom we depend may be adversely affected by earthquakes or other natura
Page 51 - Our ability to utilize our net operating loss carryforwards and certain other tax attributes may be
Page 52 - Future sales and issuances of our common stock or rights to purchase common stock, including pursuan
Page 53 - Our principal stockholders and management own a significant percentage of our stock and will be able
Page 54 - Our operating results may fluctuate significantly or may fall below the expectations of investors or
Page 55 - N/A
Page 56 - EXHIBIT INDEX
Page 57 - SIGNATURES
Subdocument 2 - EX-31.1 - EX-31.1
Page 1 - N/A
Subdocument 3 - EX-31.2 - EX-31.2
Page 1 - N/A
Subdocument 4 - EX-32.1 - EX-32.1
Page 1 - N/A
XBRL Item - EX-101.INS - XBRL INSTANCE DOCUMENT (What's this?)
XBRL Item - EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA (What's this?)
XBRL Item - EX-101.CAL - XBRL TAXONOMY EXTENSION CALCULATION LINKBASE (What's this?)
XBRL Item - EX-101.DEF - XBRL TAXONOMY EXTENSION DEFINITION LINKBASE (What's this?)
XBRL Item - EX-101.LAB - XBRL TAXONOMY EXTENSION LABEL LINKBASE (What's this?)
XBRL Item - EX-101.PRE - XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE (What's this?)
XBRL Viewer